Loading...
•
Jun 30, 2024
Veru Q3 2024 Earnings Report
Reported fiscal 2024 third quarter financial results and reached full enrollment for Phase 2b QUALITY clinical study of Enobosarm for obesity.
Key Takeaways
Veru Inc. reported an increase in net revenues to $4.0 million and a decrease in net loss to $11.0 million for the third quarter of fiscal year 2024. The company also achieved full enrollment in its Phase 2b QUALITY clinical trial for Enobosarm.
Reached targeted full enrollment of >150 patients for enobosarm Phase 2b QUALITY clinical trial.
Topline data for primary endpoint of lean body mass expected January 2025.
Net revenues increased to $4.0 million from $3.3 million.
Net loss was $11.0 million, or $0.07 per share, compared to $12.5 million, or $0.14 per share.
Veru
Veru
Forward Guidance
The company anticipates topline data in January 2025 for the Phase 2b QUALITY clinical trial and in the second calendar quarter of 2025 for the separate blinded Phase 2b extension clinical study.